David Wiss, PhD, RDN, FMCP
Founder, FxMed Mental Health
There’s a parallel between Internal Family Systems therapy and functional medicine that doesn’t get named enough. IFS says there are no bad parts — only burdened ones, carrying protective roles they took on for good reasons. Functional medicine says there are no bad symptoms — only signals from a system trying to do something for you, even when that something has become exhausting or destructive.
Both models reject the framing that something is fundamentally broken. Both ask the same question, from different angles: what is this trying to protect, and what does it need?
That convergence isn’t a marketing line. It’s an invitation to take both models seriously at the same time — and to recognize that the body you bring to your therapy session is not a neutral container. Your biological state actively shapes which parts come forward, how loud they get, and whether the inner work you do can hold.
Two models, one philosophy
Internal Family Systems, developed by Richard Schwartz, treats the psyche as a system of parts — exiles carrying pain, managers working to prevent that pain from surfacing, and firefighters that respond when the system is overwhelmed. The therapeutic goal isn’t to silence the protectors or banish the exiles. It’s to access what Schwartz calls the Self — a state of calm, curious, compassionate awareness — and help the protectors release what they’ve been carrying. The model has clinical evidence beyond what most realize. A randomized controlled trial of IFS in rheumatoid arthritis patients showed sustained improvements in depression, self-compassion, and self-assessed joint pain one year after the intervention ended, even though disease activity itself didn’t change [1].
Functional medicine treats the body with the same logic. Symptoms aren’t enemies to suppress. Inflammation, hormonal chaos, gut dysfunction, fatigue — these are outputs of a system that has been doing the best it could with the inputs it received. The clinical work isn’t to override the signal with a medication. It’s to ask what the system is responding to, and to restore the conditions under which a more regulated state becomes possible.
Both models ask “what is this doing for the person?” rather than “how do we make it go away?” That’s a real philosophical alignment, not a marketing overlap. And it’s why integrating them feels coherent rather than eclectic.
The biology underneath the parts
Here’s where functional medicine adds something that depth psychology alone cannot: a specific account of how the biological terrain shapes the psychological one.
Neuroinflammation primes the system for threat. Elevated inflammatory cytokines — IL-6, TNF-alpha, and high-sensitivity CRP — are associated with increased threat detection, anhedonia, social withdrawal, and rumination. A landmark review in Nature Reviews Immunology lays out how cross-talk between inflammatory pathways and brain circuits can shift behavior toward avoidance and alarm, and how this same machinery contributes to depression and antidepressant non-response [2]. Translated into IFS language: a brain under inflammatory load is biologically biased toward firefighter activation. Protectors emerge faster and harder. Exiles are harder to contain, because the nervous system reads ordinary stimuli as threatening. The state IFS calls “blended with a protector” has a neuroimmune correlate.
HPA axis dysregulation keeps the system in survival mode. Four decades of research, summarized in a quantitative meta-analysis of 361 studies and over 18,000 people, show consistent HPA axis hyperactivity in depression — elevated cortisol, blunted feedback inhibition, atypical diurnal patterns [3]. When a salivary cortisol panel shows a flattened cortisol awakening response or elevated evening cortisol, you’re looking at a nervous system that hasn’t been able to return to baseline. The Self cannot lead from a body still running survival physiology.
The gut-brain axis sets the floor of regulation. The vagus nerve, tryptophan metabolism, short-chain fatty acid production, and microbiome composition all directly influence emotional regulation capacity, with effects reaching the brain through immune, neural, endocrine, and metabolic pathways [4]. When stool testing reveals low short-chain fatty acid production or microbial diversity collapse, you’re not just looking at digestive concerns. You’re looking at reduced vagal input to the brain, lower GABA tone, and a narrowed window of tolerance. Heart rate variability — itself a measure of vagal function — predicts the brain’s capacity for flexible emotional regulation [5].
Nutritional substrate determines neurotransmitter capacity. A comprehensive review in Molecular Psychiatry maps the converging mechanisms by which diet shapes mental health — inflammation, oxidative stress, the gut microbiome, HPA axis function, tryptophan-kynurenine metabolism, neurogenesis, BDNF, and the epigenome — emphasizing that these are interacting, not isolated, pathways [6]. In practice: B vitamins (B6, folate, B12) are cofactors for serotonin, dopamine, and GABA synthesis. Zinc and magnesium directly modulate NMDA and GABAergic signaling. When a comprehensive nutrient panel shows depletion across these substrates, the biological capacity for emotional regulation is constrained.
None of this is a replacement for IFS. It’s the answer to a question that depth psychology can’t ask on its own: why is this client’s work harder than the protocol predicts?
When IFS work stalls
Most experienced IFS therapists know the pattern. The client makes contact with a protector, the protector begins to share — and then the system floods. The Self can’t stay in the lead. Somatic activation overwhelms the conversation. The next session arrives, and the protector is back, more guarded than before.
There are psychological explanations for this, and they’re often correct. The protector wasn’t ready. Trust hadn’t been built. The exile being approached was too tender. But sometimes the explanation lives below the psychology. A client running on chronic neuroinflammation, dysregulated cortisol, and depleted B vitamins is trying to do precision work with a nervous system that is biased toward alarm. The work isn’t failing. The terrain is making it harder than it has to be.
This is why testing matters. A baseline workup that includes inflammatory markers, HPA axis function across the day, gut microbiome composition, food sensitivities, and core nutrient status can tell you whether the body is helping or hindering the psychological work. Without that data, you’re guessing about the terrain.
The terrain enables every depth modality
The same argument extends beyond IFS. Any therapy that requires nervous system regulation — and most of the powerful ones do — works better when the biology underneath is supported.
Psychedelic medicine and biological readiness
Psychedelic-assisted therapy has emerging evidence as a catalyst for the same kind of unblending IFS works toward through different means. The Phase 3 trial of MDMA-assisted therapy for severe PTSD showed large effects on symptom reduction with substantial sustained benefit, even in patients with comorbid depression, dissociation, and substance use history [7]. A head-to-head trial comparing psilocybin to escitalopram in moderate-to-severe depression found higher response and remission rates in the psilocybin arm, though the primary endpoint comparison did not reach statistical significance [8].
These modalities work in part by transiently increasing neuroplasticity and reducing the rigidity of default-mode network activity — the same neural rigidity that makes protector parts difficult to access. But neuroplasticity is biologically expensive. A brain under sustained inflammatory load has reduced BDNF expression and impaired plasticity. The physiology underneath determines whether the medicine’s opening can become lasting change.
Worth noting honestly: the psychedelic field has real controversies, including ongoing FDA questions about MDMA-AT trial methodology and durability, and serious contraindications with serotonergic medications and certain psychiatric conditions. Set, setting, and integration are not optional. Neither is testing the terrain.
Yoga, vagal tone, and the nervous system floor
Yoga and breath-based practices make a similar argument from a different direction. A systematic review and meta-analysis of randomized controlled trials found significant short-term effects of yoga on anxiety symptoms, with particularly strong effects against active comparators in non-clinical populations [9]. The proposed mechanism is direct stimulation of the vagus nerve, increased GABAergic tone, and restoration of parasympathetic activity — a corrective to the autonomic imbalance, GABA underactivity, and elevated allostatic load that characterize many stress-driven conditions [10]. This is the same physiology that depth therapy depends on.
Yoga isn’t a substitute for trauma work, and it isn’t a substitute for testing. The research base is also heterogeneous — yoga styles, intensities, and study designs vary widely. But for clients whose biology can support consistent practice, regular vagal-stimulating movement raises the floor on which every other modality stands.
What this looks like clinically at FxMed Mental Health
At FxMed Mental Health, we run a comprehensive functional medicine workup before designing any protocol — and the testing is built around exactly this question: what is the biological state of the person in front of us, and how is it shaping the work they’re trying to do? That includes inflammatory markers, HPA axis function across the day, gut barrier and microbiome assessment, food sensitivity profiling, and nutrient status — across seven specialty panels covering blood, urine, stool, and saliva markers.
The clinical team is built around the same principle. Our collaborating psychiatrist brings neuroscience training and integrative psychiatry expertise, including clinical support for patients exploring psychedelic-assisted therapy where appropriate. Our in-house health psychologist provides psychological consultation that integrates somatic practices, mind-body medicine, and chronic illness expertise — meeting patients where their nervous systems actually are. The functional medicine and nutrition piece sits underneath, addressing the terrain on which their work happens.
This isn’t conventional psychiatry with extra labs. It isn’t depth therapy with supplements bolted on. It’s a working assumption — backed by the literature — that the body and the psyche are not parallel tracks. They’re the same system, read from different angles.
The data deserve a real conversation
If you’ve been doing IFS work and feeling like something is harder than it should be — if a yoga practice doesn’t seem to be sticking the way it does for others, if you’re curious about psychedelic medicine but uncertain whether you’re a candidate — the question worth asking isn’t whether one model is better than another.
The question is what your biology is doing while you’re trying to do the work.
You’re not treatment-resistant. You’re likely undertested.
Frequently Asked Questions
How does Internal Family Systems therapy relate to functional medicine?
IFS and functional medicine share a core philosophy: neither sees symptoms as the enemy. IFS treats psychological parts as protective rather than pathological, working to understand what they carry rather than eliminate them. Functional medicine treats physical symptoms the same way — as signals from a system trying to do something, even when that something has become costly. The two integrate because biology actively shapes which psychological parts come forward, and how easily depth work can land.
What biological factors can make IFS therapy harder?
Several measurable biological states can make depth psychological work more difficult. Chronic neuroinflammation biases the nervous system toward threat detection, making protector parts more reactive and exiles harder to safely access. HPA axis dysregulation keeps the system in survival physiology, reducing access to Self-energy. Gut microbiome disruption lowers vagal tone and GABA capacity, narrowing the window of tolerance. Nutrient depletion reduces neurotransmitter synthesis. None of this means IFS won’t work — it means the terrain may need attention too.
What lab tests are useful for understanding mental health from a functional medicine perspective?
A comprehensive functional workup typically includes inflammatory markers such as high-sensitivity CRP, a complete HPA axis assessment across the day (often via DUTCH urinary hormone testing), a comprehensive stool analysis to assess microbiome composition and gut barrier integrity, food sensitivity testing to identify immune reactivity to common foods, and a broad nutrient panel covering B vitamins, minerals, amino acids, and methylation markers. Genetic testing can add context for metabolic individuality.
How does inflammation affect mood and emotional regulation?
Inflammatory cytokines like IL-6, TNF-alpha, and high-sensitivity CRP influence neural circuits involved in threat detection, motivation, and social engagement. Elevated inflammation is associated with anhedonia, social withdrawal, rumination, and reduced antidepressant response. In a regulated state, the brain interprets ambient stimuli as neutral; under inflammatory load, the same stimuli register as threats. This is one mechanism by which chronic physical inflammation translates into chronic emotional dysregulation.
Can yoga support psychotherapy for anxiety or trauma?
Yes, with caveats. Systematic reviews of yoga for anxiety find meaningful short-term symptom improvements, particularly in non-clinical or mildly anxious populations. The proposed mechanism is direct vagal nerve stimulation, increased GABA activity, and parasympathetic restoration — the same physiology that depth therapy depends on. Yoga isn’t a substitute for trauma work, and severely dysregulated states may need biological foundation-building before yoga becomes accessible. For most clients, regular practice raises the floor on which therapy works.
Should I be evaluated before exploring psychedelic-assisted therapy?
A thorough biological and psychiatric workup is widely considered essential before any psychedelic-assisted therapy. Serotonergic medications including SSRIs and MAOIs carry significant interaction risks with most psychedelic medicines. Cardiovascular status, history of psychotic symptoms, family psychiatric history, and current medication regimen all matter. Beyond safety, a brain under sustained inflammatory load has reduced neuroplasticity, which means the same dose may produce different durability of benefit. Testing the terrain isn’t optional; it’s the foundation of safe, effective work.
References
[1] Shadick NA, Sowell NF, Frits ML, et al. A randomized controlled trial of an internal family systems-based psychotherapeutic intervention on outcomes in rheumatoid arthritis: a proof-of-concept study. J Rheumatol. 2013;40(11):1831-1841. doi:10.3899/jrheum.121465
[2] Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. doi:10.1038/nri.2015.5
[3] Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011;73(2):114-126. doi:10.1097/PSY.0b013e31820ad12b
[4] Cryan JF, O’Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877-2013. doi:10.1152/physrev.00018.2018
[5] Park G, Thayer JF. From the heart to the mind: cardiac vagal tone modulates top-down and bottom-up visual perception and attention to emotional stimuli. Front Psychol. 2014;5:278. doi:10.3389/fpsyg.2014.00278
[6] Marx W, Lane M, Hockey M, et al. Diet and depression: exploring the biological mechanisms of action. Mol Psychiatry. 2021;26(1):134-150. doi:10.1038/s41380-020-00925-x
[7] Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. doi:10.1038/s41591-021-01336-3
[8] Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994
[9] Cramer H, Lauche R, Anheyer D, et al. Yoga for anxiety: a systematic review and meta-analysis of randomized controlled trials. Depress Anxiety. 2018;35(9):830-843. doi:10.1002/da.22762
[10] Streeter CC, Gerbarg PL, Saper RB, Ciraulo DA, Brown RP. Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder. Med Hypotheses. 2012;78(5):571-579. doi:10.1016/j.mehy.2012.01.021
